Vivus: into single digits Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bradpalm1 who wrote (941)	8/29/1998 9:04:00 PM
From: BigKNY3	Read Replies (1) of 1016

Brad <<Muse will always have a niche role in the treatment of ED but it will never live up to its initial promise.>> Brad: It is still very surprising to me that there has been absolutely no coattail effect for MUSE with the growth of Viagra or patients who do not respond to Viagra. VVUS management tried to hold on to their #1 position in early 1998 and fight the pending Viagra launch with an "impotence awareness campaign", expansion of their field force, hiring of a contract PCP sale force, a direct to consumer program, and no partnering with Big Pharma. The end result is reflected in Friday's closing price. To be fair, it is unclear if a different strategy would have had any different results. But certainly, millions would have been saved and VVUS prospects would have been brighter. BigKNY3

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next